PMID- 34458019
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210831
IS  - 2167-8359 (Print)
IS  - 2167-8359 (Electronic)
IS  - 2167-8359 (Linking)
VI  - 9
DP  - 2021
TI  - Prognostic significance and tumor-immune infiltration of mTOR in clear cell renal 
      cell carcinoma.
PG  - e11901
LID - 10.7717/peerj.11901 [doi]
LID - e11901
AB  - Mammalian target of rapamycin (mTOR), a serine/threonine kinase involved in cell 
      proliferation, survival, metabolism and immunity, was reportedly activated in 
      various cancers. However, the clinical role of mTOR in renal cell carcinoma (RCC) 
      is controversial. Here we detected the expression and prognosis of total mTOR and 
      phosphorylated mTOR (p-mTOR) in clear cell RCC (ccRCC) patients, and explored the 
      interactions between mTOR and immune infiltrates in ccRCC. The protein level of 
      mTOR and p-mTOR was determined by western blotting (WB), and their expression was 
      evaluated in 145 ccRCC and 13 non-tumor specimens by immunohistochemistry (IHC). 
      The relationship to immune infiltration of mTOR was further investigated using 
      TIMER and TISIDB databases, respectively. WB demonstrated the ratio of p-mTOR to 
      mTOR was higher in ccRCC than adjacent specimens (n = 3), and IHC analysis 
      elucidated that p-mTOR expression was positively correlated with tumor size, 
      stage and metastasis status, and negatively correlated with cancer-specific 
      survival (CSS). In univariate analysis, high grade, large tumor, advanced stage, 
      metastasis, and high p-mTOR expression were recognized as prognostic factors of 
      poorer CSS, and multivariate survival analysis elucidated that tumor stage, 
      p-mTOR and metastasis were of prognostic value for CSS in ccRCC patients. Further 
      TIMER and TISIDB analyses uncovered that mTOR gene expression was significantly 
      associated with numerous immune cells and immunoinhibitors in patients with 
      ccRCC. Collectively, these findings revealed p-mTOR was identified as an 
      independent predictor of poor survival, and mTOR was associated with tumor immune 
      infiltrates in ccRCC patients, which validated mTOR could be implicated in the 
      initiation and progression of ccRCC.
CI  - (c) 2021 Li et al.
FAU - Li, Na
AU  - Li N
AD  - Department of Urology, The First Affiliated Hospital of Shandong First Medical 
      University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.
FAU - Chen, Jie
AU  - Chen J
AUID- ORCID: 0000-0003-4077-437X
AD  - Department of Urology, The First Affiliated Hospital of Shandong First Medical 
      University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.
AD  - Department of Urology, Jinan Central Hospital, Cheeloo College of Medicine, 
      Shandong University, Jinan, Shandong, China.
FAU - Liu, Qiang
AU  - Liu Q
AUID- ORCID: 0000-0002-2236-5049
AD  - Department of Cardiology, The First Affiliated Hospital of Shandong First Medical 
      University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.
FAU - Qu, Hongyi
AU  - Qu H
AD  - Department of Pediatric Surgery, The First Affiliated Hospital of Shandong First 
      Medical University & Shandong Provincial Qianfoshan Hospital, Shandong 
      Engineering and Technology Research Center for Pediatric Drug Development, Jinan, 
      Shandong, China.
FAU - Yang, Xiaoqing
AU  - Yang X
AD  - Department of Pathology, The First Affiliated Hospital of Shandong First Medical 
      University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.
FAU - Gao, Peng
AU  - Gao P
AD  - Department of Cardiology, The First Affiliated Hospital of Shandong First Medical 
      University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.
FAU - Wang, Yao
AU  - Wang Y
AD  - Department of Cardiology, The First Affiliated Hospital of Shandong First Medical 
      University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.
FAU - Gao, Huayu
AU  - Gao H
AD  - Department of Pediatric Surgery, The First Affiliated Hospital of Shandong First 
      Medical University & Shandong Provincial Qianfoshan Hospital, Shandong 
      Engineering and Technology Research Center for Pediatric Drug Development, Jinan, 
      Shandong, China.
FAU - Wang, Hong
AU  - Wang H
AD  - Department of Urology, The First Affiliated Hospital of Shandong First Medical 
      University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.
FAU - Zhao, Zuohui
AU  - Zhao Z
AUID- ORCID: 0000-0002-8391-9770
AD  - Department of Pediatric Surgery, The First Affiliated Hospital of Shandong First 
      Medical University & Shandong Provincial Qianfoshan Hospital, Shandong 
      Engineering and Technology Research Center for Pediatric Drug Development, Jinan, 
      Shandong, China.
LA  - eng
PT  - Journal Article
DEP - 20210817
PL  - United States
TA  - PeerJ
JT  - PeerJ
JID - 101603425
PMC - PMC8378334
OTO - NOTNLM
OT  - Cancer-specific survival
OT  - Mammalian target of rapamycin
OT  - Prognosis
OT  - Renal cell carcinoma
OT  - Tumor-infiltrating immune cell
COIS- The authors declare that they have no competing interests.
EDAT- 2021/08/31 06:00
MHDA- 2021/08/31 06:01
PMCR- 2021/08/17
CRDT- 2021/08/30 05:58
PHST- 2021/04/17 00:00 [received]
PHST- 2021/07/13 00:00 [accepted]
PHST- 2021/08/30 05:58 [entrez]
PHST- 2021/08/31 06:00 [pubmed]
PHST- 2021/08/31 06:01 [medline]
PHST- 2021/08/17 00:00 [pmc-release]
AID - 11901 [pii]
AID - 10.7717/peerj.11901 [doi]
PST - epublish
SO  - PeerJ. 2021 Aug 17;9:e11901. doi: 10.7717/peerj.11901. eCollection 2021.